Chugai, Eli Lilly deal
The partners will establish a 50-50 joint venture, Chugai Lilly Clinical Research Co. Ltd. (Tokyo), to develop selected Lilly compounds for the Japanese market. Chugai will staff the joint venture and will receive Japanese co-promotion and co-marketing rights to the joint venture's compounds. Lilly said that over time it expects to fund a majority of development expenses for the venture.
The venture will develop Lilly's Prozac fluoxetine antidepressant, MDR multidrug resistance inhibitor to treat cancer, tomoxetine selective noradrenergic uptake inhibitor to treat attention deficit hyperactivity disorder (ADHD) and possibly IC351, an oral phosphodiesterase 5 ( PDE5) inhibitor to treat sexual dysfunction. IC351is being developed through a joint venture between Lilly and Icos Corp. (ICOS, Bothell, Wash.). ...